Investor Polar Capital LLP
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Polar Capital LLP . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2020-02-14 13G/A / Oxford Immunotec Global PLC 2,557,973 2,568,385
2020-02-14 13G/A QTNT / Quotient Ltd 5,796,063 7,257,319
2020-02-14 13G BLU / Bellus Health Inc 3,023,625
2020-02-14 13G DERM / Journey Medical Corporation 2,841,540
2019-02-14 13G/A AVEO / AVEO Pharmaceuticals Inc 8,077,429 0
2019-02-14 13G STML / Stemline Therapeutics, Inc. 2,902,666
2019-02-14 13G/A / Oxford Immunotec Global PLC 2,465,022 2,557,973
2019-02-14 13G/A QTNT / Quotient Ltd 4,527,294 5,796,063
2019-02-14 13G/A HRTG / Heritage Insurance Holdings, Inc. 1,300,000 1,278,500
2018-02-14 13G QTNT / Quotient Ltd 4,527,294
2018-02-14 13G HRTG / Heritage Insurance Holdings, Inc. 1,300,000
2018-02-14 13G/A / Oxford Immunotec Global PLC 1,732,603 2,465,022
2018-02-14 13G AVEO / AVEO Pharmaceuticals Inc 8,077,429
2018-02-14 13G/A / Achaogen Inc 1,750,000 1,881,380
2017-03-06 13G / Achaogen Inc 1,750,000
2017-03-06 13G / Oxford Immunotec Global PLC 1,732,603
2012-02-10 13G MERU / Meru Networks Inc 1,032,004